Intervention not reported
Socioeconomic effects · people at risk for the development of type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Incidence of type 2 diabetes mellitus Measured as 2 consecutive fasting blood glucose values ≥ 6.1 mmol/L (NANSY 2011b) or no definition provided (Eriksson 2006) · people at risk for the development of type 2 diabetes mellitus
It is very uncertain whether the intervention changes incidence of type 2 diabetes mellitus Measured as 2 consecutive… (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for the development of type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Cardiovascular mortality · people at risk for the development of type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Non‐fatal myocardial infarction, non‐fatal stroke, congestive heart failure · people at risk for the development of type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Health‐related quality of life · people at risk for the development of type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Socioeconomic effects · people at risk for the development of type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality · people at risk for the development of type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Incidence of type 2 diabetes mellitus Defined as: fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) or a 2‐hour blood glucose after a glucose‐load test ≥ 11.1 mmol/L (200 mg/dL) or by an adjudication committeeb · people at risk for the development of type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Incidence of type 2 diabetes mellitus · non‐diabetic adults with insulin resistance
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Diabetic complications · non‐diabetic adults with insulin resistance
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · non‐diabetic adults with insulin resistance
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Health‐related quality of life · non‐diabetic adults with insulin resistance
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality · non‐diabetic adults with insulin resistance
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Socioeconomic effects · non‐diabetic adults with insulin resistance
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cancer occurrence · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D showed no clear difference in cancer occurrence compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Cancer occurrence in trials using vitamin D₃ (cholecalciferol) · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D showed no clear difference in cancer occurrence in trials using vitamin D₃ (cholecalciferol) compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
All‐cause mortality · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D may leads to lower all‐cause mortality compared with placebo or no intervention (low certainty).
1 finding from 1 review
Cancer mortality in trials using vitamin D3 (cholecalciferol) ( · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D may leads to lower cancer mortality in trials using vitamin D₃(cholecalciferol) compared with placebo or no intervention (low certainty).
1 finding from 1 review
Adverse events ‐ Nephrolithiasis in trials using vitamin D3 combined with calcium · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D may leads to higher adverse events: nephrolithiasis in trials using vitamin… compared with placebo or no intervention (low certainty).
1 finding from 1 review